Ethanol extract of Abelmoschus manihot suppresses endoplasmic reticulum stress in contrast-induced nephropathy

Abstract

Objective: To explore the efficacy and potential mechanisms of the ethanol extract of Abelmoschus manihot (L.) Medic in contrast-induced nephropathy (CIN). Methods: CIN rat models and human renal proximal tubular cells (HK-2) with iopromide-induced injury were employed to mimic CIN conditions. The effect of Abelmoschus manihot extract on the rat models and HK-2 cells was evaluated. In rat models, kidney function, histology, oxidative stress and apoptosis were determined. In HK-2 cells, cell viability, apoptosis, mitochondrial membrane potential, and endoplasmic reticulum stress were assessed. Results: Abelmoschus manihot extract significantly improved structural and functional impairments in the kidneys of CIN rats. Additionally, the extract effectively mitigated the decline in cellular viability and reduced iopromide-induced oxidative stress and lipid peroxidation. Mechanistic investigations revealed that Abelmoschus manihot extract prominently attenuated acute endoplasmic reticulum stress-mediated apoptosis by downregulating GRP78 and CHOP protein levels. Conclusions: Abelmoschus manihot extract can be used as a promising therapeutic and preventive agent in the treatment of CIN.

Keywords

Contrast-induced nephropathy / Abelmoschus manihot extract / ER stress / Apoptosis / GRP78 / CHOP

Acknowledgments

The authors express their sincere thanks to J. Iacona, Ph.D., from Liwen Bianji (Edanz) (www.liwenbianji.cn) for the assistance in language editing.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Funding

This study was supported by the National Natural Science Foundation of China (No. 81973762).

Data availability statement

The data supporting the findings of this study are available from the corresponding authors upon request.

Authors’ contributions

XC contributed to the conceptualization, experiment design and manuscript revision. X. Lin, X. Lu, YZ and YW contributed to the investigation and methods. RN and X. Lin contributed to the formal analysis and writing draft. The final version has been reviewed and approved by all authors.

References

[1] Pistolesi V, Regolisti G, Morabito S, Gandolfini I, Corrado S, Piotti G, et al. Contrast medium induced acute kidney injury: A narrative review. J Nephrol 2018; 31(6): 797-812.

[2] Barrett T, Khwaja A, Carmona C, Martinez Y, Nicholas H, Rogers G, et al. Acute kidney injury: Prevention, detection, and management. Summary of updated NICE guidance for adults receiving iodine-based contrast media. Clin Radiol 2021; 76(3): 193-199.

[3] Chandiramani R, Cao D, Nicolas J, Mehran R. Contrast-induced acute kidney injury. Cardiovasc Interv Ther 2020; 35(3): 209-217.

[4] Nabi Z, Anjum N, Rashid RM, Zahideen ZU. Contrast induced nephropathy in high risk patients - Myth or reality. J Ayub Med Coll Abbottabad 2021; 33(4): 568-571.

[5] Azzalini L, Kalra S. Contrast-induced acute kidney injury-definitions, epidemiology, and implications. Interv Cardiol Clin 2020; 9(3): 299-309.

[6] Liu S, Shan XG, Zhang XJ. The place of hydration using intravenous fluid in patients at risk of developing contrast-associated nephropathy. Br J Hosp Med (Lond) 2020; 81(9): 1-7.

[7] Timal RJ, Kooiman J, Sijpkens YWJ, de Vries JPM, Verberk-Jonkers I, Brulez HFH, et al. Effect of no prehydration vs sodium bicarbonate prehydration prior to contrast-enhanced computed tomography in the prevention of postcontrast acute kidney injury in adults with chronic kidney disease: The Kompas randomized clinical trial. JAMA Intern Med 2020; 180(4): 533-541.

[8] Zaki HA, Bashir K, Iftikhar H, Alhatemi M, Elmoheen A. Evaluating the effectiveness of pretreatment with intravenous fluid in reducing the risk of developing contrast-induced nephropathy: A systematic review and meta-analysis. Cureus 2022; 14(5): e24825.

[9] Rudnick MR, Leonberg-Yoo AK, Litt HI, Cohen RM, Hilton S, Reese PP. The controversy of contrast-induced nephropathy with intravenous contrast: What is the risk? Am J Kidney Dis 2020; 75(1): 105-113.

[10] Ma S, Zhao M, Chang M, Shi X, Shi Y, Zhang Y. Effects and mechanisms of Chinese herbal medicine on IgA nephropathy. Phytomedicine 2023; 117. doi: 10.1016/j.phymed.2023.154913.

[11] Luan F, Wu Q, Yang Y, Lv H, Liu D, Gan Z, et al. Traditional uses, chemical constituents, biological properties, clinical settings, and toxicities of Abelmoschus manihot L.: A comprehensive review. Front Pharmacol 2020; 11. doi: 10.3389/fphar.2020.01068.

[12] Wu Q, Lin X, Miao X, Liu F. Effect of Jiahua tablet on renal injury index in patients with contrast nephropathy after coronary angiography or interventional therapy. J Nanjing Univ Tradit Chin Med 2020; 36(2): 189-192.

[13] Lin X, Wang Y, Miao X, Gao K, Wu Q. Clinical study of Jiahua tablet in the prevention and treatment of contrast nephropathy in patients with coronary intervention. J Modern Integr Tradit Chin West Med 2020; 29(35): 3882-3885.

[14] Zhang L, Li P, Xing CY, Zhao JY, He YN, Wang JQ, et al. Efficacy and safety of Abelmoschus manihot for primary glomerular disease: A prospective, multicenter randomized controlled clinical trial. Am J Kidney Dis 2014; 64(1): 57-65.

[15] Li N, Tang H, Wu L, Ge H, Wang Y, Yu H, et al. Chemical constituents, clinical efficacy and molecular mechanisms of the ethanol extract of Abelmoschus manihot flowers in treatment of kidney diseases. Phytother Res 2021; 35(1): 198-206.

[16] Zhao J, Tostivint I, Xu L, Huang J, Gambotti L, Boffa JJ, et al. Efficacy of combined Abelmoschus manihot and irbesartan for reduction of albuminuria in patients with type 2 diabetes and diabetic kidney disease: A multicenter randomized double-blind parallel controlled clinical trial. Diabetes Care 2022; 45(7): e113-e115.

[17] Xu Z, Qian L, Niu R, Wang Y, Yang Y, Liu C, et al. Mechanism of Abelmoschus manihot L. in the treatment of contrast-induced nephropathy on the basis of network pharmacology analysis. Front Nephrol 2022; 2. doi: 10.3389/fneph.2022.834513.

[18] Li W, He W, Xia P, Sun W, Shi M, Zhou Y, et al. Total extracts of Abelmoschus manihot L. attenuates adriamycin-induced renal tubule injury via suppression of ROS-ERK1/2-Mediated NLRP3 inflammasome activation. Front Pharmacol 2019; 10. doi: 10.3389/fphar.2019.00567.

[19] Sugiura T, Hirasawa Y, Toyoshi T, Matsumura Y. Effects of agmatine on contrast-induced nephropathy in rats and rabbits. Biol Pharm Bull 2020; 43(10): 1556-1561.

[20] Iordache AM, Buga AM, Albulescu D, Vasile RC, Mitrut R, Georgiadis G, et al. Phosphodiesterase-5 inhibitors ameliorate structural kidney damage in a rat model of contrast-induced nephropathy. Food Chem Toxicol 2020; 143. doi: 10.1016/j.fct.2020.111535.

[21] Ren C, Bao X, Lu X, Du W, Wang X, Wei J, et al. Complanatoside A targeting NOX4 blocks renal fibrosis in diabetic mice by suppressing NLRP3 inflammasome activation and autophagy. Phytomedicine 2022; 104. doi: 10.1016/j.phymed.2022.154310.

[22] Zhang F, Lu Z, Wang F. Advances in the pathogenesis and prevention of contrast-induced nephropathy. Life Sci 2020; 259. doi: 10.1016/j.lfs.2020.118379.

[23] Sireesh D, Suganya N, Chatterjee S, Ramkumar KM. Gymnema montanum improves endothelial function via inhibition of endoplasmic reticulum stress by activating Nrf2 signaling. Asian Pac J Trop Biomed 2020; 10(8): 379-386.

[24] Kusirisin P, Chattipakorn SC, Chattipakorn N. Contrast-induced nephropathy and oxidative stress: Mechanistic insights for better interventional approaches. J Transl Med 2020; 18(1): 400.

[25] Mamoulakis C, Tsarouhas K, Fragkiadoulaki I, Heretis I, Wilks MF, Spandidos DA, et al. Contrast-induced nephropathy: Basic concepts, pathophysiological implications and prevention strategies. Pharmacol Ther 2017; 180: 99-112.

[26] Vlachopanos G, Schizas D, Hasemaki N, Georgalis A. Pathophysiology of contrast-induced acute kidney injury (CIAKI). Curr Pharm Des 2019; 25(44): 4642-4647.

[27] Andreucci M, Faga T, Pisani A, Sabbatini M, Michael A. Acute kidney injury by radiographic contrast media: Pathogenesis and prevention. Biomed Res Int 2014; 2014. doi: 10.1155/2014/362725.

[28] Shu S, Wang H, Zhu J, Liu Z, Yang D, Wu W, et al. Reciprocal regulation between ER stress and autophagy in renal tubular fibrosis and apoptosis. Cell Death Dis 2021; 12(11): 1016.

[29] Teng J, Liu M, Su Y, Li K, Sui N, Wang S, et al. Down-regulation of GRP78 alleviates lipopolysaccharide-induced acute kidney injury. Int Urol Nephrol 2018; 50(11): 2099-2107.

[30] Zhong Y, Jin C, Han J, Zhu J, Liu Q, Sun D, et al. Inhibition of ER stress attenuates kidney injury and apoptosis induced by 3-MCPD via regulating mitochondrial fission/fusion and Ca ²⁺ homeostasis . Cell Biol Toxicol 2021; 37(5): 795-809.

[31] Yan M, Shu S, Guo C, Tang C, Dong Z. Endoplasmic reticulum stress in ischemic and nephrotoxic acute kidney injury. Ann Med 2018; 50(5): 381-390.